Racial and ethnic differences in the mutational landscape of low-grade serous ovarian cancer

被引：0
|
作者：
Ahsan, Muhammad Danyal
Webster, Emily M.
Levi, Sarah R.
Nguyen, Natalie T.
Cubillos-Ruiz, Juan R.
Cantillo, Evelyn
Chapman-Davis, Eloise
Frey, Melissa K.
Holcomb, Kevin
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4258
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4258
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Targeting MAPK in recurrent, low-grade serous ovarian cancer Comment
    Blagden, Sarah P.
    LANCET, 2022, 399 (10324): : 499 - 501
  • [22] Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
    Lazurko, Caitlin
    Linder, Revital
    Pulman, Kate
    Lennox, Genevieve
    Feigenberg, Tomer
    Fazelzad, Rouhi
    May, Taymaa
    Zigras, Tiffany
    CURRENT ONCOLOGY, 2023, 30 (09) : 8159 - 8171
  • [23] Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer
    Nobre, Silvana Pedra
    Peplinski, Rebekah
    Schillo, Jacob
    Ulmer, Keely
    Riordan, Jesse
    Dupuy, Adam
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S305 - S305
  • [24] BinimetinibAcquired resistance in low-grade serous ovarian cancer: case report
    Reactions Weekly, 2020, 1789 (1) : 67 - 67
  • [25] Advances in precision therapy of low-grade serous ovarian cancer: A review
    Wang, Qing
    Cao, Sheng-Han
    Li, Yan-Yu
    Zhang, Jing-Bo
    Yang, Xin-Hui
    Zhang, Bei
    MEDICINE, 2024, 103 (17) : E34306
  • [26] Stage I low-grade serous ovarian cancer: Is there a benefit to chemotherapy?
    Vue, Nujsaubnusi
    Horne, Zachary
    Crafton, Sarah
    Krivak, Thomas
    Miller, Eirwen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S286 - S286
  • [27] Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer
    Karacin, Cengiz
    Sunar, Veli
    Urakci, Zuhat
    Yilmaz, Ali
    Ayhan, Murat
    Ersoy, Mustafa
    Guven, Deniz Can
    Erturk, Ismail
    Durmus, Yasin
    Karacin, Pinar
    Boran, Nurettin
    Ustun, Yaprak Engin
    Meydan, Mutlu
    Dogan, Mutlu
    Oksuzoglu, Berna
    Ates, Ozturk
    Karaca, Mustafa
    Uncu, Dogan
    Ergun, Yakup
    Arik, Zafer
    FUTURE ONCOLOGY, 2024, 20 (04) : 207 - 214
  • [28] New therapeutic opportunities for women with low-grade serous ovarian cancer
    Moujaber, Tania
    Balleine, Rosemary L.
    Gao, Bo
    Madsen, Ida
    Harnett, Paul R.
    DeFazio, Anna
    ENDOCRINE-RELATED CANCER, 2022, 29 (01) : R1 - R16
  • [29] Racial differences in the tumor immune landscape and survival of high-grade serous ovarian carcinoma
    Peres, Lauren C.
    Colin-Leitzinger, Christelle
    Sinha, Sweta
    Marks, Jeffrey R.
    Conejo-Garcia, Jose R.
    Alberg, Anthony J.
    Bandera, Elisa V.
    Berchuck, Andrew
    Bondy, Melissa L.
    Christensen, Brock C.
    Cote, Michele L.
    Doherty, Jennifer A.
    Moorman, Patricia G.
    Segura, Carlos Moran
    Nguyen, Jonathan V.
    Peters, Edward S.
    Schwartz, Ann G.
    Terry, Paul D.
    Wilson, Christopher M.
    Fridley, Brooke L.
    Schildkraut, Joellen M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [30] Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma
    Santillan, A.
    Kim, Y. W.
    Zahurak, M. L.
    Gardner, G. J.
    Giuntoli, R. L., II
    Shih, I. M.
    Bristow, R. E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (03) : 601 - 606
12345